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V IRAL hepatitis is a major disease indication for liver 
transplantation. Both fulminant hepatic failure due 
to any of a number of hepatotrophic viruses such as 
hepatitis A. B. C. B+D. -E. cytomega!ovirus (CMV). 
Epstein-Barr (EBV), herpes, or NANBNC and chronic 
hepatitis associated with cirrhosis and liver failure due to 
hepatitis B. C. B+D, or NANBNC are among the four or 
five more frequent specific indications for liver transplan-
tation at most transplant centers. For this later group of 
patients. in particular. with chronic viral liver disease. 
disease recurrence is an important clinical problem follow-
ing successful transplantation. 1-3 
Two issues of particular concern relative to viral hepa-
titis following liver transplantation are the effects of the 
required immunosuppressive agent upon viral replication 
and the role. if any, of interteron therapy upon either 
rejection induction or persistence. Because of the size of 
the transplant program at the University of Pittsburgh and 
the availability of both cycJosporine (CyA) and FK 506 as 
:..,munosuppressive agents at this institution. experience 
with both agents has been obtained in liver allograft 
recipients with either recurrent or de novo viral hepatitis 
who have been treated with a-interteron. 
MATERIALS AND METHODS 
Subjects 
:\ total of 84 liver allograft reCIpients with viral hepalllls have been 
treated With a-intertcron. [wenty-two of these indiViduals were 
reCelVln1! eVA. and 62 were receiving FK 506 as their maJor 
Immunosuppressive agent. Twenty-eight of these hepallc allograft 
reCIpients had hepalllls-B. 37 had hepatuis-C. and II} had hepall-
IIs-NANBNC as the cause of their hepalllls, 
Disease Detection 
Abnonnal liver Injury tests. panlcularly abnonnalities of the 
aminotransferase levels that were resistant to minor changes an 
t he immunosuppressIve regtmen. or that were not allnbutable to a 
reco!ZOIzed drug toxicity. identified an allograft recipient as requIr-
ing a liver biopsy. Immedlatelv pnor to each liver biopsy. a 
~omplcte panel of Viral serolollic studies. Including assays for 
HAV, HBV, HCV. HOV. EBV. and CMV was obtained. A 
pcrcutaneous liver biopsy was obtained from each with a Tru-cut 
needle and was processed by the Clinical Pathology Department. 
Therapv and Disease Monitonng 
Individuals Identified as descnbed above. who were found to have 
a liver biOpsy consIstent with viral hepatitis consisting of a pattern 
llf lobular inflammation and patchy hepatocellular necrosIs. as 
well as a mononuclear cell infiltrate In the ponat areas. but 
wllhout eVidence of acute cellular rejection t vasculitis or bile duct 
tnluro. were treated wllh tt-Interteron tSchenngl at a dose of 5 
million U. 3 times a week. for 6 months. During the course of 
interferon therapy, the liver injury parameters (ALT. AST. bili-
rubin. and atkaline phosphatase I. as well as hematologic parame-
ters (WBC and platelet counts I. were monitored weekly for the 
tirst month. then twice monthly for a second month. and then 
monthly until the tennination of a 6-month course of therapy. 
After 6 months. a second liver biopsy was obtained and the 
interferon therapy was discontinued. Six weeks later. a third liver 
biopsy was obtained and the liver injury parameters were assessed 
monthly thereafter. for an additional 6 months. 
Response Definitions 
A full response was defined as a complete nonnalization of the 
assessed liver Injury parameters tALT and AST levels) and in the 
case of HOV disease. a seroconversion from HBeAg-posltive to 
HBeAb-positive. 
A partial response was defined as a greater than SO% reducuon 
in the baseline liver injury parameters. but not a complete 
normalization of these parameters of liver injury, 
RESULTS 
The time from date of transplantation to the'time at which 
the viral hepatitis in liver allograft recipients was docu-
mented histologically is shown in Table I. Hepatitis due to 
the HBV tended to occur earlier than did hepatitis C or 
NANBNC hepatitis in these allograft recipients. More 
importantly. (hose receiving FK 506 developed their hep-
atitis earlier (han did those who were receiving CyA. 
regardless of the type of hepatitis. 
Overall. 10% of the patients treated experienced a 
complete remtssion: 50% experienced a partial remission. 
while 40% failed to respond to a 6-month course of 
a-intert'eron therapy at the dose utilized. The response 
rates for those IOdividuals receIving FK 506 as their 
primary immunosuppressive agent were less than those 
receiving Cy A. and consisted of fewer individuals experi-
encing a partIal remission and a slightly greater number of 
Table 1. Time to HeplitiU. Following fran.pIantatIon 
VilUl FK !lO8 
HBV 381 :!: 53 
HeV 564 :t 88 
NANBNC 599:!: 162 
All S18:!: 102 
<;~ 1991 by Appleton & Lange 
0041·1345191/$3.001+0 
evA PVI/ue 
991 % 210 <001 
1348 :!: 313 <,002 
910 % 235 NS 
1082:!: 235 <0001 
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ALL FOAMS OF HEPATmS 
Fig 1. The bars show the percentage of patients in each group 
treated with either FK 506 or CyA expenenang a full. partial. or no 
response to 6 months of Interferon therapy. 
nonresponders (Fig I). Despite the normalization (full 
response) or greater than 50% reduction in the levels of the 
assessed measures of liver injury (partial response). the 
liver histology failed to improve in most subjects. Worse 
yet. as assessed by the Knodell criteria for disease activ-
ity.' the histologic disease either remained stable in a third 
of the subjects studied or worsened slightly in the remain-
ing two thirds. 
DISCUSSION 
This is the first report of the use of a-interferon in a large 
group of liver allograft recipients treated for viral hepatitis 
occurring after successful transplantation. Several obser-
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vations can be made as a result of this unique experience. 
First. immunosuppression with FK 506. as compared to 
CyA. is associated with a statistically earlier onset of 
posttransplant hepatitis. regardless of the specific type of 
hepatitis being considered. More importantly. FK 506. as 
compared to eVA. is associated with a reduced number of 
clinical responses to a-interferon therapy. Third. despite a 
good clinical response as assessed by liver injury parame-
ters. the histologic evidence for viral hepatitis in liver 
allograft recipients either remain unchanged or actually 
worsens as a result or during the period of interferon 
therapy. Fourth. and importantly. no episodes of acute 
cellular rejection or cases of chronic rejection were ascrib-
able to the use of a-interferon in these allograft recipients. 
These data suggest that the enhanced immunosuppression 
associated with FK 506 as opposed to CyA results in an 
enhanced rate of viral replication and. as a reSUlt. a 
reduction in the number of responses to a-interferon 
therapy experienced. Moreover. these data suggest that 
the use of newer and more powerful immunosuppressive 
agents such as FK 506 mandate the identification and use 
of more specific antlviral agents if viral hepatitis is to be 
successfully treated in liver allograft recipients. 
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